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 3 
1 Abstract 
 
Obesity poses a serious human health risk. Obese patients usually take prescription 
drugs that require hepatic and renal metabolism and transport, and these patients some-
times display different pharmacokinetics of these drugs. As demonstrated in animal stud-
ies, metabolic disturbances such as diabetes or obesity can significantly affect renal and 
hepatic gene expression including xenobiotic transporters. Moreover, reduced renal mass 
seems to enhance the changes in gene expression. In this study we analyzed the impact 
of diet-induced obesity and uninephrectomy on renal and hepatic gene expression. 
mRNA level of OATPs (organic anion transporting polypeptides) and FXR (farnesoid X 
receptor) target genes were measured in kidneys and livers of female C57/BJ mice. To 
assess the effect of diet-induced obesity in a state of reduced renal mass, mice underwent 
uninephrectomy followed by either a normal chow or high-fat diet and were compared 
with sham-operated control mice. Gene expression analysis was performed using real-
time PCR (polymerase chain reaction). We observed that the hepatic and renal mRNA 
expression of OATPs is affected mainly by the high-fat diet. Uninephrectomy had no sig-
nificant impact on renal and hepatic gene expression in this study. Immunohistochemical 
staining of Oatp1a1 indicates that the decreased mRNA expression was also consistent 
at the protein level. Additionally, in silico analysis indicates that not only FXR, but also 
other transcription factors such as PPARα (peroxisome proliferator-activated receptor al-
pha) is directly or indirectly involved in the regulation of OATPs. In summary, the expres-
sion of a number of xenobiotic transporters and FXR regulated genes was significantly 
altered in livers and kidneys of diet-induced obese mice. Because transporter genes are 
frequently regulated by similar mechanisms in mouse and human, the data from this study 
suggest that transporter expression in human liver and kidney may be affected by obesity, 
leading to altered pharmacokinetics and potentially drug-drug interactions. 
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2 Introduction 
 
The growing epidemic of obesity is certainly one of the biggest challenges in health care 
this century. The prevalence of obesity has almost doubled between 1980 and 2008 and 
is still increasing. According to the WHO (World Health Organization), obesity is among 
the leading risk factors for mortality worldwide [1]. It is well known that obesity is associ-
ated with several comorbidities such as diabetes, hypertension and dyslipidemia. Obesity 
not only affects the cardiovascular system, but also organs such as the liver and kidney. 
Non-alcoholic fatty liver disease (NAFLD) is known to be frequently associated with obe-
sity, type 2 diabetes and dyslipidemia [2, 3]. Moreover, obesity is considered an inde-
pendent risk factor for the development of chronic kidney disease (CKD) and progression 
to end-stage renal disease [4, 5]. Obesity is a major risk factor for CKD in patients with 
reduced renal mass [6]. Moreover, metabolic disturbances such as diabetes or obesity 
can significantly affect renal and hepatic gene expression [7, 8]. Global gene expression 
analysis in the mouse kidney revealed a substantial number of differentially expressed 
genes in obese mice after a 20-week high-fat diet. In addition to genes involved in lipid 
metabolism, cytoskeleton remodeling and fibrosis, genes from the organic anion trans-
porting polypeptide (OATP) transporter family showed altered expression in diet-induced 
obesity in mice. Furthermore, the effect of a high-fat diet on gene expression was accen-
tuated in obese mice with a reduced renal mass (uninephrectomy). According to pathway 
analysis, the farnesoid X receptor (FXR) signaling pathway was shown to be one of the 
top pathways that was activated in the remnant kidney of obese mice [8].  
 
FXR (gene name NR1H4) is a member of the nuclear receptor family and functions as a 
ligand-activated transcription factor. FXR is mainly expressed in the liver and the intes-
tine, and plays a critical role in bile acid (BA) homeostasis by regulating BA synthesis, BA 
uptake into hepatocytes, biliary BA secretion, intestinal BA reabsorption and secretion. 
FXR is activated by free or conjugated bile acids, among which chenodeoxycholic acid 
(CDCA) is the most potent ligand. The activated FXR can serve as a transcriptional acti-
vator or repressor of gene expression. FXR activation increases BA conjugation, BA ef-
flux from the hepatocytes into bile and inhibits hepatic BA synthesis as well as intestinal 
BA uptake [9, 10]. BAs exert an important role in regulation of cholesterol and triglyceride 
metabolism. Bile acid sequestrants in the enterohepatic circulation increase both bile acid 
and VLDL triglyceride synthesis. Conversely, CDCA-mediated increases in the BA pool 
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size leads to inhibition of BA synthesis and reduced serum triglycerides in hyperlipidemic 
patients [11, 12]. These effects of BA to modulate triglyceride metabolism are likely me-
diated via several distinct mechanisms, predominantly activation of FXR. FXR alters the 
transcription of several genes involved in fatty acid and triglyceride synthesis and lipopro-
tein metabolism [11]. Thus, FXR may play a critical role under obese conditions.  
 
Liver and kidney play critical roles in drug metabolism and elimination. While liver is the 
principal site of detoxification and degradation, the kidney is mainly involved in excretion 
of drugs. Hepatic drug elimination consists of (1) uptake from the portal blood, (2) metab-
olism and (3) biliary excretion. Drug clearance in the kidney is determined by (1) glomer-
ular filtration, (2) tubular secretion and (3) reabsorption [13]. The cellular uptake and ex-
cretion of endo- and xenobiotics are mediated through a variety of membrane transport-
ers. Transporters expressed in mammalian key organs like liver, kidney and the small 
intestine are important determinants of drug absorption, distribution and elimination [13, 
14]. According to their function, transporter proteins can be classified into uptake and 
efflux transporters. Whereas transporters mediating the uptake into the cell belong to the 
SLC (solute carriers) superfamilies, most efflux proteins are members of the ABC (ATP-
binding cassette) transporter superfamily [14, 15]. Within the SLC transporters, the or-
ganic anion transporting polypeptides (OATPs, gene name SLCO), organic cation/anion 
transporters (OCTs and OATs, gene name SLC22A), and the oligopeptide transporters 
(PEPTs, gene name SLC15A) are considered the most important subfamilies with phar-
macological relevance [16]. OATPs are a group of membrane transporter proteins with a 
wide spectrum of substrates. They mediate the sodium-independent transport of amphi-
pathic compounds such as bile salts, steroid conjugates, thyroid hormones, anionic oli-
gopeptides, numerous drugs and other xenobiotic substances. Although some members 
in rodents and humans are predominantly, if not exclusively expressed in liver, most 
OATP/Oatp family members are expressed in multiple tissues including brain, kidney and 
intestine [17, 18]. Due to their wide substrate spectrum and their expression in several 
tissues, Oatps are important for the absorption, distribution, and excretion of drugs.  
Therefore, altered expression of these uptake transporters may affect drug transport ki-
netics, which in turn affects drug response in different patients.  
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Among other nuclear receptors, FXR modulates a wide range of target genes including 
endo- and xenobiotic transporters from the OATP families [19, 20]. Since these transport-
ers play important roles in drug disposition and elimination, an alteration in their expres-
sion can considerably change drug pharmacokinetics leading to the loss of drug efficacy 
or unexpected toxicity [21]. Given these observations and the rising number of obese 
people and obese living kidney donors in the world population [22], proper investigation 
of these transporters and their regulation under obese and uninephrectomized conditions 
using a rodent model will provide valuable information to aid in the prediction of drug 
efficacy, pharmacokinetics, and toxicity in morbidly obese patients and living kidney do-
nors. 
 
In the present study we analyzed the impact of diet-induced obesity and uninephrectomy 
on the renal and hepatic expression of OATPs as well as other FXR target genes. High-
fat-diet-fed mice were used as an obesity model. We compared gene expression between 
sham operated mice fed with chow diet (sham-chow, control), sham operated mice fed 
with high-fat diet (sham-HFD), uninephrectomized mice with chow diet (UNX-chow) and 
UNX mice with high-fat diet (UNX-HFD). We observed that the hepatic and renal gene 
expression of OATPs is mainly affected by the high-fat diet. Uninephrectomy had no sig-
nificant impact on renal and hepatic gene expression in this study. Immunohistochemical 
staining of Oatp1a1 indicated that changes in mRNA expression were also detectable at 
the protein level. Additionally, in silico analysis indicates that not only FXR, but also other 
transcription factors such as PPARα is directly or indirectly involved in the regulation of 
OATPs.  
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3 Material and Methods 
 
3.1 Animals 
 
Female C57/BJ mice were randomly assigned into 4 groups of 6 mice: sham procedure 
with chow diet (sham-chow/control), sham with high fat diet (sham-HFD), uninephrectomy 
(UNX) with chow diet (UNX-chow) and UNX with high fat diet (UNX-HFD). Uninephrec-
tomy and sham procedure were performed at the age of 6 weeks. Thereafter, the mice 
received either a normal chow diet (Provimi Kliba AG, Kaiseraugst, Switzerland) or a high-
fat diet (Provimi Kliba AG, Kaiseraugst, Switzerland) for 20 weeks according to their as-
signment. Kidneys and livers were harvested 20 weeks after surgery and the mice were 
sacrificed. The isolated liver and kidney tissues were kept in 1.5ml Safe-Lock tubes and 
stored at -80°C. 
 
3.2 RNA extraction 
 
RNA extraction from kidney and liver samples was accomplished by using TRIzol® rea-
gent (Life Technologies, USA). 1ml of TRIzol was added to each sample and the tissues 
were minced and homogenized by using 1.5ml pestles and a mixer (Polytron). To permit 
complete dissociation of the nucleoprotein complex the samples were incubated for 2-
3min at room temperature. Subsequently, 0.2ml of chloroform was added and the sam-
ples were centrifuged (12‘000g, 15min, 4°C) to separate RNA from DNA and other cellular 
proteins. After centrifugation, RNA remained in an upper aqueous phase whereas DNA 
and proteins were present in the interphase and a lower phenol phase. The upper phase 
with the RNA was removed and transferred to new RNase-free tubes. Thereafter, 500μl 
of 100% isopropanol was added to precipitate the RNA within the aqueous phase. After 
a further centrifugation (12’000g, 15min, 4°C), an RNA pellet was formed at the bottom 
of the tube. The supernatant was removed and the pellet was washed twice with 80μl of 
75% ethanol. After discharging the ethanol, the RNA pellets were left to air dry at room 
temperature for 5-10min. Depending on the pellet’s size 20-100μl of RNase-free water 
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were used to resuspend the pellet. The RNA concentrations were determined by spec-
trophotometry using Nanodrop (Witec AG, Switzerland). The sample purity was assessed 
by the A260/280 ratio, which ideally ranged between 1.8 and 2.0. 
 
3.3 cDNA synthesis 
 
The High Capacity cDNA Reverse Transcription Kit (Life Technologies, USA) was used 
to synthesize single-stranded cDNA out of mRNA. 5μg RNA of kidney samples and 2μg 
RNA of liver samples were used for reverse transcription. The standard reaction mix and 
total reaction volume for 1μg RNA were adapted respectively and the RNA was mixed up 
with an appropriate amount of RNase-free water, half of the final reaction volume. The 
samples were incubated according to the scheme given by the manufacturer. 
 
Table 1: Reverse transcription mixtures 
 Standard Kidney Liver 
RNA (μg) 1 5 2 
RNA + ddH2O (μl) 10 40 20 
    
Reverse Transcription Buffer (μl) 2.0 8.0 4.0 
dNTPs (μl) 0.8 3.2 1.6 
Random Primers (μl) 2.0 8.0 4.0 
Reverse Transcriptase (μl) 1.0 4.0 2.0 
RNase Inhibitor (μl) 1.0 4.0 2.0 
ddH2O (μl) 3.2 12.8 6.4 
Total reaction volume (μl) 20 80 40 
 
 
3.4 Relative quantification of gene expression 
 
Aliquots of synthesized cDNA were used as template for real-time PCR. Gene expression 
was analyzed using real-time PCR (TaqMan). For each target gene a master mixture 
containing primer and probe was prepared. Master mixture and sample aliquots were 
pipetted on a 384-well reaction plate. The reaction volume per well was 10μl, containing 
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2μl of the sample and 8μl master mixture. The samples were arranged in triplicates (3 
wells per gene per sample). β-actin was used as housekeeping gene (reference gene) 
for both tissue types (kidney and liver). The 2 –ΔΔCt method [23, 24] was applied to analyze 
the changes in gene expression. The Ct (cycle threshold) values provided from real-time 
PCR were imported into a Microsoft Excel sheet. Means and standard deviations of Ct 
values were determined for target and reference gene in each sample. Using the 2 –ΔΔCt 
method, the data are presented as the fold change in gene expression normalized to β-
actin and relative to the reference sample from the control group (sham chow). The fold 
change in the target gene normalized to β-actin and relative to the control, was assessed 
for each sample. 
 
3.5 Immunohistochemical staining of Oatp1a1 in the liver 
 
To evaluate the protein expression of Oatp1a1 in formalin-fixed paraffin-embedded liver 
sections the microwave based antigen retrieval technique was used. First, the sections 
were deparaffinized in two 5min changes of xylene, rehydrated through a graded series 
of ethanol (100%, 95% and 80%, 5min each) and rinsed in distilled water. After immersing 
in a staining dish containing 10 mM citrate buffer (pH 6.0), the sections were placed in 
the microwave for 3 cycles of 1 – 5min (each cycle until boiling point). Thereafter, the 
slides were left at room temperature to cool down for 20min and washed in distilled water. 
Subsequently, the slides were placed in 3%-H2O2 at room temperature for 20min, 
washed 3x 5min with PBS (phosphate buffered saline), immersed in 5% milk/PBS at room 
temperature for 30min and rinsed briefly in distilled water. The sections were incubated 
with the first rabbit anti-Oatp1a1 antibody (8) overnight at 4°C. Sections were again 
washed with PBS (3x 5min), HRP (Horseradish peroxidase)-polymer anti-rabbit antibody 
was added, slides were incubated at room temperature for 30 min and washed with PBS 
(3x 5min). HRP was detected using DAB (3,3’-Diaminobenzidine). 
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3.6 In silico analysis of Slco1a1 (Oatp1a1) promotor region 
 
In silico analysis of the Slco1a1 promotor region was performed to identify putative FXR 
response elements (IR1, 5’ AGTTCAnTGAACT 3’). 2000 base pairs upstream from the 
transcription start (NCBI Reference Sequence: NC_000072.6) were analyzed by visual 
inspection, using MatInspector (Genomatix software) and Nubiscan (University Basel).  
 
3.7 Statistical analyses 
 
Changes in gene expression were calculated in Microsoft Excel. The statistical analysis 
was performed with the GraphPad Prism software. A one-way ANOVA followed by a Bon-
ferroni’s test was used for comparison of the four groups. P-values < 0.05 were consid-
ered as significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11 
3.8 List of materials and chemicals 
 
1.5 ml Pestle (VWR International, USA) 
1.5 ml Safe-Lock Tubes (Eppendorf AG, Germany) 
2-Propanol ≥ 99.5% (Sigma-Aldrich, USA) 
50 ml Polypropylene Conical Tube (BD Biosciences, USA) 
Centrifuge 5417 R (Vaudaux-Eppendorf, Switzerland) 
Centrifuge 5810 R (Vaudaux-Eppendorf, Switzerland) 
Chloroform 99% (Sigma-Aldrich, USA) 
Ethanol for molecular biology ≥99.8% (Merck KGaA, Germany) 
GraphPad Prism software (GraphPad, USA) 
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Life Technologies, 
USA) containing: 
10X RT Buffer 
10X RT Random Primers 
25X dNTP Mix (100 mM) 
MultiScribe® Reverse Transcriptase (50 U/µL) 
MicroAmp Optical 384-Well reaction plate (Applied Biosystems, Life Technologies, USA) 
MicroAmp Optical Adhesive Film (Applied Biosystems, Life Technologies, USA)  
Multipette plus (Vaudaux-Eppendorf, Switzerland) 
NanoDrop ND-1000 Spectrophotometer (Witec AG, Switzerland) 
Nuclease-free water (Ambion, Life Technologies, USA) 
PicoFuge (Stratagene Cloning Systems, Agilent Technologies, USA) 
PT 1200 C Mixer (Polytron, Kinematica AG, Switzerland) 
RNAse free 1.5 ml Microfuge Tubes (Ambion, Life Technologies, USA) 
TaqMan Fast Universal PCR Master Mix (Applied Biosystems, Life Technologies, USA) 
Thermomixer comfort (Vaudaux-Eppendorf AG, Switzerland) 
TRIzol Reagent (Ambion, Life Technologies, USA) 
ViiA 7 Real-Time PCR System (Applied Biosystems, Life Technologies, USA) 
Vortex-Genie 2 (Scientific Industries, USA) 
Xplorer 5-100 ul (Vaudaux-Eppendorf, Switzerland) 
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4 Results 
 
4.1 Effect of uninephrectomy and high fat diet on body weight 
 
Mice fed with the high-fat diet had a markedly increased body weight compared to those 
with the normal chow diet.  There was no significant difference in body weight between 
the UNX-mice and their counterparts with the sham surgery in both diet groups (Table 2).  
 
Table 2: Body weight in the different groups after 20 weeks of diet 
 Sham chow Sham HFD UNX chow UNX HFD 
Body weight in g 
(mean ± SD) 
19.5 ± 0.6 28.8 ± 4.3 21.0 ± 0.6 29.2 ± 2.9 
 
p < 0.05: sham-chow vs. sham-HFD, UNX-chow vs. UNX-HFD 
p > 0.05: sham-chow vs. UNX-chow, sham-HFD vs. UNX-HFD 
Abbreviations: SD, standard deviation; HFD, high fat diet; UNX, uninephrectomy 
 
 
4.2 Gene expression in mouse kidney from different treatment groups 
 
Membrane transporter genes along with FXR regulated genes in the mouse kidney were 
examined using semi-quantitative PCR analysis to determine the effect of diet-induced 
obesity and uninephrectomy on their expression and regulation. The genes selected for 
investigation in this study are listed in Table 3. Figures 1 and 2 illustrate the PCR results. 
The expression of each gene is plotted as the fold change normalized to β-actin and 
relative to the control group (Sham-chow). The four groups were compared as follows: 
Sham-chow versus Sham-HFD, UNX-chow versus UNX-HFD, Sham-chow versus UNX-
chow and Sham-HFD versus UNX-HFD.  
 
Among the investigated Oatps in the kidney no significant changes in gene expression 
were observed with the exception of Oatp1a1 and Oatp1b2 (Figure 1). Mice fed with a 
high-fat diet showed a marked decrease of Oatp1a1 and Oatp1b2 in the kidney compared 
to the chow diet. Whereas Oatp1b2 expression was significantly lower in both Sham-HFD 
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and UNX-HFD mice, the shift in Oatp1a1 expression in the Sham-HFD group did not 
reach statistical significance compared with the sham-chow. There was no difference in 
the expression of Oat2 (organic anion transporter 2, gene Slc22a7) between the groups. 
Oat2 may not be affected by either HFD or UNX in the kidney (Figure 1). The expression 
level of FXR in the sham-HFD and UNX-chow groups seemed to be decreased, although 
the changes did not reach statistical significance. Shp (small heterodimer partner), which 
is regulated by FXR activation, was increased in the Sham-HFD and UNX-HFD mice; yet, 
its deviation in the UNX-HFD group was not statistically significant (Figure 2). Taken to-
gether, the impact of high-fat diet on renal Oatp gene expression was stronger than that 
of uninephrectomy. Moreover, an enhancing effect of UNX on changes in gene expres-
sion of transporters in the kidney could not be observed.  
 
Table 3: List of tested genes 
Gene symbol Protein 
Nr1h4 Fxr 
Nr0b2 Shp 
Slco1a1 Oatp1a1 
Slco1a4 Oatp1a4 
Slco1b2 Oatp1b2 
Slco2b1 Oatp2b1 
Slc22a7 Oat2 
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Fig. 1: Expression of Oatps and Oat2 in mouse kidney from different treatment groups. Data are shown as 
mean ± SEM, *p < 0.05 
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4.3 Gene expression in the liver 
 
Since UNX could also affect bile acid transporters in the liver [25], expression analysis for 
the same genes as tested in the kidney (Table 3) was performed in liver tissues of the 
different treatment groups. Whereas Shp seemed to be increased in the Sham-HFD and 
UNX-HFD groups, the expression of Fxr revealed no relevant changes (Figure 3). Similar 
to the results in the kidney, Oatp1a1 expression in the liver was lower in the high-fat diet 
groups. In contrast to the findings in the kidney, the expression of Oatp1b2 was not al-
tered in the liver. Oatp1a4 and Oatp2b1 showed no differences in expression level be-
tween the four groups (Figure 4). Furthermore, hepatic expression of Oat2 was decreased 
in mice fed with a high-fat diet. Similar to the observation in the kidney, the impact of a 
high-fat diet on hepatic gene expression was stronger than that of uninephrectomy. No 
additional effect of UNX on the changes in gene expression of transporters in the liver 
was observed.  
 
 
 
 
Fig. 2: mRNA expression level of FXR and Shp in the kidney from different treatment groups. Data are 
shown as mean ± SEM, *p < 0.05. 
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Fig. 3: mRNA expression of Fxr and Shp in mouse liver. Data are shown in mean ± SEM, *p < 0.05. 
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Fig. 4: Expression of transporter genes in mouse liver. Data shown as mean ± SEM,  
*p < 0.05. 
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4.4 Immunostaining of Oatp1a1 in the liver 
 
To evaluate the protein expression of Oatp1a1, immunohistochemistry staining was per-
formed in liver tissues comparing the sham-chow and sham-HFD groups. As shown in 
Figure 6, the expression of Oatp1a1 was lower in the sham-operated mice fed with a 
high-fat diet. Further, hepatic steatosis was observed in the Sham-HFD group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: Immunohistochemical staining of liver samples with antibo-
dies against Oatp1a1. The brown color indicates positive staining. A) 
Mice from the sham-chow/control group showed an unremarkable 
hepatic tissue and normal expression of Oatp1a1. B) Mice from the 
sham-HFD group with decreased expression of Oatp1a1 and hepatic 
steatosis as secondary finding. 
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4.5 In silico analysis of Oatp1a1 (Slco1a1) promotor region 
 
Since Oatp1a1 has been reported as a FXR target gene [8], in silico analysis of the 
Oatp1a1 promotor region was performed to identify putative FXR response elements ar-
ranged as inverted repeats (IR1, 5’ AGTTCAnTGAACT 3’). A region spanning 2000 base 
pairs upstream of the transcription start (NCBI Reference Sequence: NC_000072.6) was 
analyzed. Inverted repeats (IR1, 5’ AGTTCAnTGAACT 3’) could not be found in this frag-
ment. However, several PPARα binding sites were found. As shown by Cheng et al. [26], 
Oatp1a1 expression can be repressed by activation of different transcription factors in-
cluding aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR), preg-
nane X receptor (PXR), nuclear factor erythroid 2-related factor 2 (Nrf2), and PPARα 
(peroxisome proliferator-activated receptor). Considering the fact that the high-fat diet 
used in this study contained a high load of free fatty acids (coconut oil, a potent PPARα 
ligand), PPARα seemed to be the most probable among the nuclear receptors that were 
evaluated (not listed here). Typical response elements for PPARα are direct repeats, DR1 
and DR2 sequences [27]. Table 4 shows the putative PPARα binding sequences reported 
by the program Nubiscan. The sequence 5’ TGACCTaTGATCT 3’ (AGATCAtAGGTCA 
on the negative strand) showed the best matching core elements and is depicted in Figure 
6. Cheng et al. [28] mentioned this sequence as a putative PPARα response element in 
Oatp1a1 promotor.   
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Repeat Position (strand) p-value Sequence (5’ to 3’) 
DR1 1879 (-) 0.0019112 AGATCAtAGGTCA 
IR0 1069 (+) 0.0034975 AGGGCATCACCT 
DR8 1872 (-) 0.0045267 AGGTCAatctcattTGGACA 
DR1 1145 (+) 0.0145049 AGGCCAgAGTTTA 
DR7 487 (+) 0.0198807 AGGTCActtgttaAGTGGA 
ER7 1874 (+) 0.0433879 TGATCTagcatgtAGTGGA 
IR8 1853 (+) 0.0178256 TGTCCAaatgagatTGACCT 
IR0 776 (+) 0.0538986 TGGTCATTTCCT 
DR0 1139 (+) 0.0239962 AGCTTAAGGCCA 
 
Table 4: List of putative PPARα response elements in the mouse Oatp1a1 promotor spanning 2000 base 
pairs proximal to the transcription start site. Sequences were identified using the program Nubiscan.  Com-
pared to the other sequences the DR1 (labeled) at the top had the best matching core elements in the 
sequence. 
 
-390 TGCCAGATTGGCGCACTGCAGTGATCCTGTTCTTT-
GGGTCTTCCCAGTGATGGGCTTACAGGCATGTGAA 
 
-320 GAGAAGCCTAGCTCTTTTACTTGCCTGGTAA-
TAATTAAAAGTCAGGGCCTCAA-
GCTTAAAAAAAATCAAA 
 
-250 CACTTTACCACTGAACCACCAC-
CTCCCTATCTGTGCTGGACAGTTTTATATGAATTT-
GACATTCACTAGA 
 
-180 GTAATTTGGGAAGAGTGGCCTTCTGTTGA-
GAAAAATGTCCAAATGAGATTGACCTATGATCTAG-
CATGTA 
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-110 GTGCATTTTCTTTATTTATAATT-
GACATGTGAAGGTCTAGCACATGG-
TAGGTGGGTCTTGTTTGGTAGGT 
 
-40 AGTCCTGGGTTGTATAAGAAGGTCAAGCAAGTCTT-
GAGGA(TS) 
 
 
Fig. 6: Promotor region of Slco1a1 (Oatp1a1); 390 base pairs upstream from the transcription start (TS). 
Putative PPARα- binding site (labeled).  
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5 Discussion 
 
It is well known that obesity is a physical condition with a range of short- and long-term 
health complications. A large body of literature indicates that obesity is a major risk factor 
for liver and kidney disease. It can be either the cause or an aggravating factor when 
other conditions such as hypertension and diabetes are established [4, 5, 29, 30]. To 
date, the pathophysiological mechanisms underlying obesity-related liver and kidney dis-
ease have not been fully clarified. There is increasing evidence that the endocrine and 
immunomodulatory properties of the adipose tissue contribute to the development of or-
gan damage [5, 31, 32]. Moreover, in the recent years, several studies have revealed a 
great impact of obesity on the expression of renal and hepatic drug transporters including 
OATPs in obese and diabetic mouse models [7, 8, 33]. Among other cell-membrane-
transporters, OATPs have attracted increasing interest for their role in drug disposition 
and metabolism.  Due to their capacity to transport a wide range of xenobiotics including 
pharmaceuticals and toxins, the OATPs are considered to play essential roles in drug 
absorption, distribution and elimination. However, their physiological and pharmacologi-
cal functions remain elusive and are yet subject of ongoing research.  
 
The current study revealed a clear impact of obesity on renal and hepatic expression of 
Oatps in the high fat diet-induced obese mouse model. While the effect of the high-fat 
diet on Oatp expression was evident, uninephrectomy did not show a relevant impact on 
transporter expression in both kidney and liver. These findings suggest that the decrease 
in transporter expression is mainly caused by the high-fat diet.  
 
Of interest, Oatp1a1 (Slco1a1) was decreased in both liver and kidney of obese mice 
after a 20-week-high-fat diet intervention. Moreover, the immunohistochemistry staining 
showed a markedly reduced expression of Oatp1a1 in the liver of obese mice (Figure 6). 
These results are in line with the previous results from our lab [8], which showed lower 
expression of Oatp1a1 in the kidney of obese mice. Other authors also described down-
regulation of Oatp1a1 in obese, type 1 and type 2 diabetic mice [16, 33]. Oatp1a1 is highly 
expressed in the liver and kidney. Among other Oatps it is located at the basolateral 
membrane of hepatocytes and at the apical membrane of proximal tubules in the kidney. 
It mediates the transport of bile acids, steroid conjugates, hormones and numerous drugs 
[18, 34]. Digoxin, methotrexate, fexofenadine, and toxins such as phalloidin are known 
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substrates for Oatps [35-37]. However, pharmaceuticals, which are selectively trans-
ported through Oatp1a1, are still unknown. Knockout studies have shown that loss of 
Oatp1a1 changes the bile acid composition in the intestine and the profile of the intestinal 
microbiota. Furthermore, Oatp1a1-null mice were shown to have a markedly different bile 
acid profile in the feces, with a decrease in conjugated primary bile acids (taurine-, gly-
cine-, and sulfate-conjugated bile acids) and an elevation of secondary bile acids [38]. 
Zhang et al. [39] also demonstrated that Oatp1a1-null mice are more sensitive to choles-
tatic liver injury. Moreover, due to its function as a drug transporter, a decrease of 
Oatp1a1 could alter the absorption, distribution and excretion of certain pharmaceuticals, 
leading to alterations of pharmacokinetics, efficacy and toxicity of substrate compounds. 
The fact that there are no human homologues of mouse Oatp1a1 with a high level of 
expression in hepatocytes [35, 36] may raise some question on the overall relevance of 
Oatp1a1 to hepatic drug metabolism in humans. However, Oatp1a1 has been shown to 
share a wide range of substrates with human OATP1B1 and 1B3 [18]. Thus, the functions 
of human OATP1B1 and 1B3 are also possibly preserved in mouse Oatp1a1. Hence, 
study in mice provides important clues for further investigation and tests in humans. 
 
The regulation of Oatp1a1 has not been extensively studied, particularly with regard to 
nuclear receptor involvement. In silico analysis of the Oatp1a1 promotor region revealed 
no putative binding sites for FXR, but several PPARα response elements were found 
(Tab. 4, Fig.6). However, in silico analysis depends on the algorithm implemented and 
cannot claim completeness or correctness. While the best matching PPARα binding site 
(DR1, 5’ TGACCTaTGATCT 3’) found was detected by NUBISCAN (University Basel) 
and by visual inspection, it was surprisingly not detected by MatInspector Software. The 
fact that other authors [28] have described this sequence as a putative PPARα binding 
element supported our finding. However, only the minimal promotor spanning a 2 kb re-
gion was analyzed. FXR binding elements could be located outside of this selected frag-
ment. It is well established that FXR typically binds to inverted repeats (IR1), but as 
demonstrated by Laffitte et al. [40], FXR can also modulate gene expression through di-
rect repeats (DR4 and DR5 elements), which were not included in our analysis. Interest-
ingly, FXR activation can induce PPARα expression [41]. Thus, it is possible that FXR 
modulates Oatp1a1 expression indirectly through PPARα activation. Interestingly, SHP, 
a FXR regulated transcription factor, seemed to be elevated in diet-induced obese mice 
(Figures 1, 3), although without significant change in the UNX mice. SHP is a member of 
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the “orphan” nuclear receptors and mainly acts as transcriptional repressor. SHP can be 
induced through several transcription factors (TFs) including FXR, HNF4α, PXR, and ERα 
and exerts its transcriptional activity through protein-protein interaction with those TFs. 
Fenofibrate, a PPARα agonist, has been shown to decrease Oatp1a1 expression in the 
mouse liver [26, 42]. It has also been shown to increase SHP gene expression in cultured 
liver cells and in normal as well as in diabetic mouse liver [43, 44]. Given the current 
findings from the gene expression analysis and the fact that the high-fat diet used had a 
high concentration of PPARα ligands (coconut oil), it is conceivable that the down-regu-
lation of Oatp1a1 in this setting was at least partly mediated through PPARα.  
 
Oatp1b2 expression in the kidney was significantly decreased in the high-fat diet groups, 
whereas the hepatic expression showed no difference between the four groups. Regard-
ing the renal expression, the current findings are consistent with previous studies [8, 33]. 
However, Oatp1b2 is almost exclusively expressed in the liver and is considered the ma-
jor liver-specific uptake transporter for drugs and other xenobiotics [45]. Oatp1b2 has two 
human orthologs (OATP1B1 and 1B3), and mediates the hepatic uptake of known 
OATP1B substrates such as pravastatin and rifampicin [46]. Meier zu Schwabedissen et 
al. [47] reported that most of the nonhepatic expression of Oatp1b2 appears due to splice 
variants of Oatp1b2. It is still not clear whether these splice variants are fully functional. 
The results of our study indicate that the expression of Oatp1b2 in the kidney might be 
affected by diet-induced obesity.  
 
While the hepatic expression of Oat2 was decreased in mice fed with a high-fat diet, Oat2 
expression in the kidney did not change after HFD. Other studies have demonstrated 
decreased Oat2 expression in kidney and liver of obese rodents [8, 33]. Oat2 belongs to 
the family of the organic anion transporters (gene symbol SLC22/Slc22) and has the high-
est expression levels in the liver with lower levels in the kidney. Typical substrates for 
Oat2 include salicylates, acetylsalicylate, prostaglandin E2, dicarboxylates, glutamate, 
and PAH (para-aminohippuric acid), as well as some antivirals. Oat2 also mediates the 
transport of propionate, a short-chain fatty acid, which is a natural ligand for receptors 
inducing leptin release. Thus, Oat2 may play a critical role in the regulation of leptin se-
cretion [48]. Decreased expression of Oat2 could affect the metabolism of fatty acids and 
the pharmacokinetics of certain drugs. However, the relationship between altered meta-
bolic state and Oat2 expression remains to be elucidated. 
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In conclusion, this study demonstrated that diet-induced obesity considerably alters renal 
and hepatic expression of xenobiotic transporters in mice, especially the organic anion 
transporting polypeptides Oatp1a1 and Oatp1b2. Moreover, in silico analysis suggests 
that the regulation of Oatp1a1 expression may involve several members of the nuclear 
receptor family of transcription factors. Further studies need to be conducted to elucidate 
the functional consequences of these changes in expression. Because some drug me-
tabolizing enzymes and transporters are regulated similarly in mice and humans, the 
changes in the expression levels of homologous transporters observed in mice can be 
extrapolated to humans, with implications for the pharmacokinetics of substrate drugs in 
obese human individuals.  
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